Vera Therapeutics, Inc. (VERA)

Market Cap	2.91B +33.0%
Revenue (ttm)	n/a
Net Income	-299.62M
EPS	-4.66
Shares Out	71.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,312,038
Open	40.76
Previous Close	42.35
Day's Range	40.26 - 41.71
52-Week Range	18.53 - 56.05
Beta	1.15
Analysts	Strong Buy
Price Target	76.60 (+87.79%)
Earnings Date	Feb 26, 2026

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 224
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA
• Website: https://veratx.com

Analyst Summary

According to 11 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price target is $76.6, which is an increase of 87.79% from the latest price.

Price Target

$76.6

(87.79% upside)

Analyst Consensus: Strong Buy